| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| David Koczerginski, Larry Arshof. Hospital resource use by patients with schizophrenia: reduction after conversion from oral treatment to risperidone long-acting injection. Healthcare quarterly (Toronto, Ont.). vol 14. issue 1. 2011-06-15. PMID:21301245. |
hospital resource use by patients with schizophrenia: reduction after conversion from oral treatment to risperidone long-acting injection. |
2011-06-15 |
2023-08-12 |
Not clear |
| N V Govorin, A I Vasil'ev. [Effect of haloperidol and risperidone on neuromarkers and indices of endothelial dysfunction in patients with acute schizophrenia]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. vol 111. issue 3. 2011-06-02. PMID:21423116. |
[effect of haloperidol and risperidone on neuromarkers and indices of endothelial dysfunction in patients with acute schizophrenia]. |
2011-06-02 |
2023-08-12 |
Not clear |
| N V Govorin, A I Vasil'ev. [Effect of haloperidol and risperidone on neuromarkers and indices of endothelial dysfunction in patients with acute schizophrenia]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. vol 111. issue 3. 2011-06-02. PMID:21423116. |
effect of haloperidol and risperidone on positive, negative, neurocognitive disorders, biological parameters and neurodestruction-neuroreparation processes have been studied in 23 patients with the first episode of paranoid schizophrenia. |
2011-06-02 |
2023-08-12 |
Not clear |
| Ibrahim Turkoz, Cynthia A Bossie, Jean-Pierre Lindenmayer, Nina Schooler, Carla M Canus. Paliperidone ER and oral risperidone in patients with schizophrenia: a comparative database analysis. BMC psychiatry. vol 11. 2011-06-01. PMID:21299844. |
paliperidone er and oral risperidone in patients with schizophrenia: a comparative database analysis. |
2011-06-01 |
2023-08-12 |
Not clear |
| M Fuller, K Shermock, P Russo, M Secic, R Dirani, S Vallow, S Flander. Hospitalisation and resource utilisation in patients with schizophrenia following initiation of risperidone long-acting therapy in the Veterans Affairs Healthcare System. Journal of medical economics. vol 12. issue 4. 2011-05-24. PMID:19817665. |
hospitalisation and resource utilisation in patients with schizophrenia following initiation of risperidone long-acting therapy in the veterans affairs healthcare system. |
2011-05-24 |
2023-08-12 |
Not clear |
| M Fuller, K Shermock, P Russo, M Secic, R Dirani, S Vallow, S Flander. Hospitalisation and resource utilisation in patients with schizophrenia following initiation of risperidone long-acting therapy in the Veterans Affairs Healthcare System. Journal of medical economics. vol 12. issue 4. 2011-05-24. PMID:19817665. |
to examine hospitalisation rates and resource utilisation following initiation of risperidone long-acting therapy (rlat) among us veterans with schizophrenia. |
2011-05-24 |
2023-08-12 |
Not clear |
| Jean-Pierre Lindenmayer, Anzalee Kha. Galantamine augmentation of long-acting injectable risperidone for cognitive impairments in chronic schizophrenia. Schizophrenia research. vol 125. issue 2-3. 2011-05-23. PMID:20850275. |
galantamine augmentation of long-acting injectable risperidone for cognitive impairments in chronic schizophrenia. |
2011-05-23 |
2023-08-12 |
Not clear |
| Leslie Citrom. A review of aripiprazole in the treatment of patients with schizophrenia or bipolar I disorder. Neuropsychiatric disease and treatment. vol 2. issue 4. 2011-05-17. PMID:19412492. |
its tolerability profile in patients with schizophrenia appears superior to haloperidol, perphenazine, risperidone, and olanzapine. |
2011-05-17 |
2023-08-12 |
Not clear |
| Adel Gabrie. Gabapentin adjunctive to risperidone or olanzapine in partially responsive schizophrenia: an open-label pilot study. Neuropsychiatric disease and treatment. vol 6. 2011-05-17. PMID:21127689. |
gabapentin adjunctive to risperidone or olanzapine in partially responsive schizophrenia: an open-label pilot study. |
2011-05-17 |
2023-08-12 |
Not clear |
| b' Rogelio Apiquian, Rodrigo C\\xc3\\xb3rdoba, Mario Louz\\xc3\\xa. Clinical outcomes of long-acting injectable risperidone in patients with schizophrenia: six-month follow-up from the Electronic Schizophrenia Treatment Adherence Registry in Latin America. Neuropsychiatric disease and treatment. vol 7. 2011-05-17. PMID:21326651.' |
clinical outcomes of long-acting injectable risperidone in patients with schizophrenia: six-month follow-up from the electronic schizophrenia treatment adherence registry in latin america. |
2011-05-17 |
2023-08-12 |
Not clear |
| Shahin Akhondzadeh, Raofeh Ghayyoumi, Farzin Rezaei, Bahman Salehi, Amir-Hossein Modabbernia, Azad Maroufi, Gholam-Reza Esfandiari, Mehrangiz Naderi, Fariba Ghebleh, Mina Tabrizi, Shams-Ali Rezazade. Sildenafil adjunctive therapy to risperidone in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled trial. Psychopharmacology. vol 213. issue 4. 2011-05-13. PMID:20949350. |
sildenafil adjunctive therapy to risperidone in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled trial. |
2011-05-13 |
2023-08-12 |
Not clear |
| Kenneth L Subotnik, Keith H Nuechterlein, Joseph Ventura, Michael J Gitlin, Stephen Marder, Jim Mintz, Gerhard S Hellemann, Leslie A Thornton, Indira R Sing. Risperidone nonadherence and return of positive symptoms in the early course of schizophrenia. The American journal of psychiatry. vol 168. issue 3. 2011-05-11. PMID:21205805. |
risperidone nonadherence and return of positive symptoms in the early course of schizophrenia. |
2011-05-11 |
2023-08-12 |
Not clear |
| Cheng-Yuan Chen, Tai-Yueh Lin, Chia-Chun Wang, Hua-An Shua. Improvement of serum prolactin and sexual function after switching to aripiprazole from risperidone in schizophrenia: a case series. Psychiatry and clinical neurosciences. vol 65. issue 1. 2011-05-06. PMID:21265942. |
improvement of serum prolactin and sexual function after switching to aripiprazole from risperidone in schizophrenia: a case series. |
2011-05-06 |
2023-08-12 |
Not clear |
| John M Kane, Steven G Potkin, David G Daniel, Peter F Buckle. A double-blind, randomized study comparing the efficacy and safety of sertindole and risperidone in patients with treatment-resistant schizophrenia. The Journal of clinical psychiatry. vol 72. issue 2. 2011-05-03. PMID:20673553. |
a double-blind, randomized study comparing the efficacy and safety of sertindole and risperidone in patients with treatment-resistant schizophrenia. |
2011-05-03 |
2023-08-12 |
Not clear |
| Gahan Pandina, Rosanne Lane, Srihari Gopal, Cristiana Gassmann-Mayer, David Hough, Bart Remmerie, George Simpso. A double-blind study of paliperidone palmitate and risperidone long-acting injectable in adults with schizophrenia. Progress in neuro-psychopharmacology & biological psychiatry. vol 35. issue 1. 2011-05-03. PMID:21092748. |
a double-blind study of paliperidone palmitate and risperidone long-acting injectable in adults with schizophrenia. |
2011-05-03 |
2023-08-12 |
Not clear |
| Gahan Pandina, Rosanne Lane, Srihari Gopal, Cristiana Gassmann-Mayer, David Hough, Bart Remmerie, George Simpso. A double-blind study of paliperidone palmitate and risperidone long-acting injectable in adults with schizophrenia. Progress in neuro-psychopharmacology & biological psychiatry. vol 35. issue 1. 2011-05-03. PMID:21092748. |
this 13-week double-blind study was designed to assess noninferiority of the recently approved (in the u.s.) injectable atypical antipsychotic paliperidone palmitate (pp) versus risperidone long-acting injectable (ris-lai) in adult patients with schizophrenia. |
2011-05-03 |
2023-08-12 |
Not clear |
| Sung Joon Cho, Keunyoung Yook, Borah Kim, Tai Kiu Choi, Kang Soo Lee, Yong Woo Kim, Ji Eun Lee, Shinyoung Suh, Ki Hwan Yook, Sang-Hyuk Le. Mirtazapine augmentation enhances cognitive and reduces negative symptoms in schizophrenia patients treated with risperidone: a randomized controlled trial. Progress in neuro-psychopharmacology & biological psychiatry. vol 35. issue 1. 2011-05-03. PMID:21095214. |
mirtazapine augmentation enhances cognitive and reduces negative symptoms in schizophrenia patients treated with risperidone: a randomized controlled trial. |
2011-05-03 |
2023-08-12 |
Not clear |
| Sung Joon Cho, Keunyoung Yook, Borah Kim, Tai Kiu Choi, Kang Soo Lee, Yong Woo Kim, Ji Eun Lee, Shinyoung Suh, Ki Hwan Yook, Sang-Hyuk Le. Mirtazapine augmentation enhances cognitive and reduces negative symptoms in schizophrenia patients treated with risperidone: a randomized controlled trial. Progress in neuro-psychopharmacology & biological psychiatry. vol 35. issue 1. 2011-05-03. PMID:21095214. |
this preliminary study aimed to determine if adding mirtazapine to risperidone might improve negative and cognitive symptoms in schizophrenia. |
2011-05-03 |
2023-08-12 |
Not clear |
| Sung Joon Cho, Keunyoung Yook, Borah Kim, Tai Kiu Choi, Kang Soo Lee, Yong Woo Kim, Ji Eun Lee, Shinyoung Suh, Ki Hwan Yook, Sang-Hyuk Le. Mirtazapine augmentation enhances cognitive and reduces negative symptoms in schizophrenia patients treated with risperidone: a randomized controlled trial. Progress in neuro-psychopharmacology & biological psychiatry. vol 35. issue 1. 2011-05-03. PMID:21095214. |
in an 8-week, double-blind clinical trial, we randomly assigned 21 stabilized outpatients with schizophrenia undergoing risperidone treatment to adjunctive treatment with either mirtazapine or a placebo. |
2011-05-03 |
2023-08-12 |
Not clear |
| Sung Joon Cho, Keunyoung Yook, Borah Kim, Tai Kiu Choi, Kang Soo Lee, Yong Woo Kim, Ji Eun Lee, Shinyoung Suh, Ki Hwan Yook, Sang-Hyuk Le. Mirtazapine augmentation enhances cognitive and reduces negative symptoms in schizophrenia patients treated with risperidone: a randomized controlled trial. Progress in neuro-psychopharmacology & biological psychiatry. vol 35. issue 1. 2011-05-03. PMID:21095214. |
this study suggests augmenting risperidone with mirtazapine can effectively improve both negative and some cognitive symptoms of schizophrenia. |
2011-05-03 |
2023-08-12 |
Not clear |